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Abstract
Bovine spongiform encephalopathy (BSE) surveillance programs have been employed in numerous countries to monitor BSE
prevalence and to protect animal and human health. Since 1999, the European Commission (EC) authorized the evaluation
and approval of 20 molecular based tests for the rapid detection of the pathological prion protein (PrP
sc) in BSE infection.
The diagnostic sensitivity, convenience, and speed of these tests have made molecular diagnostics the preferred method for
BSE surveillance. The aim of this study was to determine the analytical sensitivity of 4 commercially available BSE rapid-test
kits, including the PrionicsH-Check WESTERN, the PrionicsH Check-PrioSTRIP
TM, the BioRadH TeSeE
TM ELISA, and the IDEXXH
HerdChek
TM EIA. Performances of these tests were then compared to 2 confirmatory tests, including the BioRadH TeSeE
TM
Western Blot and the modified Scrapie Associated Fibrils (SAF)/OIE Immunoblot. One 50% w/v homogenate was made from
experimentally generated C-type BSE brain tissues in ddH2O. Homogenates were diluted through a background of BSE-
negative brainstem homogenate. Masses of both positive and negative tissues in each dilution were calculated to maintain
the appropriate tissue amounts for each test platform. Specific concentrated homogenization buffer was added accordingly
to maintain the correct buffer condition for each test. ELISA-based tests were evaluated using their respective software/
detection platforms. Blot-protocols were evaluated by manual measurements of blot signal density. Detection limitations
were determined by fitted curves intersecting the manufacturers’ positive/negative criteria. The confirmatory SAF
Immunoblot displayed the highest analytical sensitivity, followed by the IDEXXH HerdChek
TM EIA, Bio-RadH TeSeE
TM Western
Blot, the Bio-RadH TeSeE
TM ELISA, PrionicsH-Check PrioSTRIP
TM, and PrionicsH-Check WESTERN
TM, respectively. Although the
tests performed at different levels of sensitivity, the most sensitive and least sensitive of the rapid tests were separated by 2
logs in analytical sensitivity, meeting European performance requirements. All rapid tests appear suitable for targeted BSE
surveillance programs, as implemented in Canada.
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Introduction
Bovine Spongiform Encephalopathy (BSE) is a fatal and, thus far,
untreatable neurodegenerative disease that affects a variety of
mammals, including humans. Public sensitivity to BSE has become
intense due to the European outbreak of bovine spongiform
encephalopathy (BSE) in the 1980s and 1990s [1–4]. Ensuing cases
of a variant form of Creutzfeldt-Jakob disease (vCJD) in humans
began appearing, and has been largely attributed to the consump-
tion of tainted products from BSE infected cattle [1,2,5]. Concerns
overBSEarealsoexacerbatedduetothe obscurenature ofinfection
and transmissibility through foodconsumption[5,6].The consumer
of BSE-contaminated foods may not show clinical signs of infection
until a number of years later, thus making the source of the
infectious material difficult to trace. Incubation periods for disease
progressioncantakebetween fourtosixyearsincattle,andfromten
to fifteen years in humans [5].
The major cause for the outbreak was the recycling of meat and
bone-meal by-products (MBM) from slaughtered animals, where it
was used as an additive in livestock feed to boost nutritional value.
Livestock consuming the BSE-contaminated feeds would become
infected and further propagate the disease upon their slaughter. As
this was a cyclic process, the rate of infectious MBM entering the
feed system, as well as the rate of newly infected animals, increased
exponentially [4,7].
A principle method to control the threat of BSE in human food
products is the surveillance of livestock destined for slaughter and
consumption. Prior to current active-surveillance programs, BSE
surveillance had been done by passive-surveillance, which relied
on farmers and veterinarians to visibly identify animals clinically
symptomatic for BSE [4]. These animals present themselves as
ataxic, or display exaggerated behaviours [8]. Once molecular
diagnostic test became available, active-surveillance programs
were started in Switzerland with a targeted surveillance, where
cattle that were dead, down, distressed, or diseased were selected
to be tested for BSE [4].
In 1999, the European Commission (EC) evaluated four BSE tests
designed to detect the disease associated BSE prion-protein
isoforms [9]. In 2001, the European Union implemented a testing
regime for slaughtered cattle, recommending that over the age of
30 months be tested [3,4,10,11]. By the end of 2002, two thirds of
European BSE cases were discovered by rapid-tests used in active-
surveillance programs [12]. Currently, commercially available
BSE rapid-tests are a vital component to monitor the efficacy of a
country’s BSE surveillance program.
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of the prion protein. The cellular form of the prion (PrP
c)i saG P I -
anchored membrane-glycoprotein, and is commonly found in many
cell-types— predominantly neurons [5,13,14]. The disease associated
prion conformer, PrP
sc, is amyloidogenic and cytotoxic, and is believed
to possess the ability to convert PrP
c into PrP
sc upon molecular contact
[13,14]. Unique physical properties of the prion protein are exploited
in order to detect its presence in tissues. PrP
sc is more resistant to
protease digestion than PrP
c [5,13–16]. When PrP
sc is exposed to
proteinase K (PK), western blot results show three distinct glycoforms
of the protein, where each glycoform is differentiated by a quantitative
ratio and molecular weight from one another. Analysis of these
glycoform ratios and their respective molecular weights is use to
i d e n t i f yt h et y p eo fB S E ,w h e t h e ri ti sclassical-BSE or an atypical form
[15,17]. When PrP
cis exposed to PK, it is mostly digested, and no PrP-
relevant bands can usually be detected [15].
The PrP
sc isoform possesses a different tertiary structure than
PrP
c. The native PrP
c exists in a a-fold, where as PrP
sc presents
itself in a b-fold [5,14,18]. Conformational detection technology
takes advantage of this property to selectively capture PrP
sc,
without compromising PrP
sc presence by a potential over exposure
to proteases. This is done using conformation-dependant antibod-
ies and/or synthetic ligands [16,19].
This aim of this study is to extend the current knowledge of BSE
diagnostic tests by identifying a theoretical limit-of-detection
(L.O.D.) for each of four commercially available BSE rapid-test
kits, as well as two confirmatory tests. The four rapid-tests kits are
the PrionicsH-Check PrioSTRIP
TM, Bio-RadH TeSeE
TM ELISA,
PrionicsH-Check WESTERN
TM, and IDEXXH HerdChek
TM BSE
EIA—all of which are used for surveillance and/or disease
confirmation in the Canadian BSE Reference Laboratory. The
four surveillance tests have been evaluated, and approved for use,
by the EC via the European Food Safety Authority (EFSA) [9,20,21].
The confirmatory tests in this study are the Canadian BSE
Reference Laboratory’s rendition of the Scrapie Associated Fibril Test
(S.A.F.)/O.I.E immunoblot [22,23], as well as the commercially
available Bio-RadH TeSeE
TM Western Blot. The primary evalua-
tion of these rapid-tests focused mainly on the diagnostic specificity
and sensitivity on a large number of field samples [9,20]. However,
this study aims to characterize the analytical sensitivity of these
tests by defining each test’s detectable penultimate dilution of an
initially strong BSE-positive sample. Each test was challenged with
the same BSE-positive material—consistent in strain and PrP
sc
concentration—which originated from an experimentally infected
bovine sacrificed with endstage clinical disease.
By serially diluting confirmed strong BSE-positive material into
a background of confirmed BSE-negative material, each test was
evaluated over diminishing levels of an identical strain of BSE
PrP
sc in a consistent background of non-infectious PrP
c. This study
aimed to characterize each test’s behaviour and performance as
the number of infectious BSE units (PrP
sc) became scarcer.
Although detection limitations are outlined as per diagnostic
criteria within the manufacturers’ instructions, this study considered a
theoretical L.O.D. for each test, based on elevatednegative or aberrant
results. Being critical of such results could help identify extremely
weak positive BSE cases, based on the knowledge of each tests
performance over low PrP
sc concentrations (analytical sensitivity).
Materials and Methods
Experimental BSE Infections and Homogenate
Preparation
To generate the pooled experimental BSE sample for intra
cranial inoculations, rostral medulla from a classical (C-type)
Canadian BSE field case was homogenized in phosphate buffered
saline (PBS) {2.7 mM KCl; 1.5 mM K(PO4); 8.1 mM Na2(PO4);
137 mM NaCl; pH: 7.460.2} to a final concentration of 10%w/v
using a MediFAST/Prypcon system. Homogenates were then
transferred to 2 mL microfuge tubes and centrifuged at 500rcf for
10 minutes. Supernatants were collected and transferred to
1.5 mL microfuge tubes, in 1.5 mL aliquots. Homogenates were
stored at 220uC. All tissues, homogenates, and inoculum were
created and stored in a biosafety level-3 (BSL-3) facility.
For intra cranial cattle inoculations (protocol #05001), the
aforementioned homogenates were thawed, sonicated 3 times (30 s
per sonication), then centrifuged for 10 minutes at 500rcf.
Supernatants were aspirated into syringes, fitted with 16-gauge
needles. Two 6 month old calves were sedated and inoculated
intracerebrally with the positive inoculum through a small hole
drilled in the cranium. Each animal received 1 mL (,100 mg C-
type BSE tissues) of homogenate. Animals were observed until
clinical symptoms were apparent and the animal was deemed
BSE-positive. Animals were euthanized, followed by post-mortem
examination and tissue collection, in a BSL-3 post-mortem facility.
Central nervous system tissues were collected and stored at -80uC.
The experimental procedure was approved by the Burnaby-
Lethbridge Animal Care Committee (BLACC), protocol #05001.
Preparation of Diagnostic Test Homogenates
Tissues from the medulla oblongata, thalamus, and colliculus of
the two inoculated calves were trimmed and confirmed for
positive-reactivity using the PrionicsH -Check PrioSTRIP
TM (results
not shown). Medulla oblongata, thalamus, and colliculus tissues
were then homogenized in de-ionized water (ddH2O) water to a
final concentration of 50%w/v and pooled. A pool of BSE
negative-tissue macerate, confirmed negative by S.A.F./O.I.E.
Immunoblot (results not shown), was created from brainstem
material from randomly selected Canadian surveillance samples of
17 bovines. The macerate was aliquoted and stored at 280uC. A
BSE-negative 50%w/v homogenate in ddH2O was created from
the macerate. All 50%w/v homogenates were homogenized using
a hand-held homogenizing unit.
Rapid Test Setup and Execution
PrionicsH-Check WESTERN
TM. Negative 50%w/v homo-
genate was homogenized using Prionics’H Priogenizer to a final
concentration of 10%w/v in 1x kit homogenization buffer.
Homogenate was appropriately aliquoted into a 96 sample plate.
Positive 10%w/v homogenate (in 1x homogenization buffer) was
added to the first well, and then serially diluted across the plate.
The dilutions were loaded on to a PrionicsH-Check WESTERN
TM
digestion plate, and the test was conducted as per the
manufacturer’s instructions. All 17-well, 12% SDS-PAGE pre-
cast gels (Invitrogen
TM) were run in MOPS SDS-PAGE running
buffer with antioxidant (Invitrogen
TM) at room temperature. Wet
transfers were performed in transfer buffer (40.34 mM glycine;
118.98 mM Tris; 2.47 M methanol), which was continuously cooled
to 4uC with a coolant-circulating system and coil. TBST buffer
(2.69 mM KCl; 136.90 mM NaCl; 24.76 mM Tris; 0.45 mM Tween
20; pH: 7.4) was used to dilute the kit antibodies, and used for all
washing steps. CDP-Star
TM (Roche) was used as the
chemiluminescent substrate for the alkaline-phosphatase [15,24].
Blots were detected using x-ray film, GBX developer, and GBX
fixer (Kodak). Film exposure times were assayed at 4, 8, 16, and 32
minutes; development time for all exposures was 35 seconds. All
films were fixed for 3 minutes. The best balanced exposure was
selected for the analysis.
The Analytical Sensitivity of 6 BSE Tests
PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e17633PrionicsH-Check PrioSTRIP
TM. Using the PrionicsH Priog-
enizer, 50%w/v negative and positive homogenates where
homogenized to a final 10%w/v homogenate in 1x PrionicsH
homogenization buffer. The negative homogenates were pooled
and appropriately aliquoted into a 96-well sample plate. An
aliquot of 10%w/v positive tissue (in 1x PrionicsH -Check
PrioSTRIP
TM homogenization buffer) was added to the first well
of the plate, and serially diluted across the plate in 10%w/v
negative homogenates. Diluted positive samples were then loaded
on a digestion-plate, and the test was executed as per the PrionicsH -
Check PrioSTRIP
TM package insert [25]. Combs were then scanned
using the appropriate scanner (Perfection V700 Photo, Epson) and
software (PrioSCAN
TM v3.0) provided by PrionicsH.
Bio-RadH TeSeE
TM ELISA. To account for excess ddH2Oi n
50%w/v negative and positive homogenates, buffer within the kit
tissue grinding tubes was lyophilized using a SpeedVacH System
(Thermo Savant) in order to concentrate the grinding buffer (45uC
x 5.1 inHg x 3 h). Negative 50%w/v homogenate was added to
the tubes (350 mg tissue mass); one tube was loaded with 50%w/v
positive homogenate (350 mg tissue mass). DdH2O was added to
adjust the tissue concentration to 25%w/v, as required by the kit
protocol. Samples were again homogenized, using the TeSeE
TM
Precess 48 homogenizing system [26].
Negative homogenates were diluted to 25%w/v and pooled.
The positive homogenate was serially diluted throughout the
negative homogenates. The dilutions were aliquoted (250 mL) into
2 mL microfuge tubes, and the test was performed as per the
manufacturer’s manual method instructions. All wash steps were
conducted by automated PW40 plate washers (Bio-RadH Labora-
tories), as supplied by Bio-RadH Laboratories. ELISA plates were
analyzed using the Model 680TSE microplate reader (Bio-RadH
Laboratories) and affiliated software [26].
IDEXXH HerdChek
TM (Bovine Spongiform Encephalop-
athy Antigen Test Kit, EIA). Sample grinding tubes were
lyophilized using a SpeedVacH System (Thermo) to concentrate the
grinding buffer (45uC x 5.1inHg x 3 h). 600 mL of 50%w/v
negative homogenate (300 mg tissue mass) was distributed into the
lyophilized buffer tubes. DdH2O was used to restore the tubes to
the original tube buffer volume, bringing the homogenate to a 1x
buffer environment. The BSE positive tube was prepared in an
identical manner.
All negative tubes were pooled and redistributed in the
appropriate aliquots. The BSE positive homogenate was serially
diluted across the negative tubes. The remainder of the test was
continued as per the manufacturer’s instructions. All wash steps
were done by automated plate washers. The antigen capture plate
was analyzed using a Bio Tek ELX 800 microplate reader, supplied
by IDEXXH Laboratories [27].
Confirmatory Test Setup and Execution
Bio-RadH TeSeE
TM Western Blot. Preparation of negative
homogenates and positive dilutions were prepared identically to
Figure 1. The curves depict densities of PrP
sc bands (diglycosylated (Digly), monoglycosylated (Monogly), unglycosylated (Ungly))
in the PrionicsH-Check WESTERN
TM western blot. Numbers on the right of each density data point correspond to the numbers in the blot photo
(inset). Only odd numbered data points appear in the blot photo. Each label (Digly, Monogly, Ungly) in the inset photo appears to the left of the band
it describes. Inset text and arrows indicate detection limitations. R
2: Digly=0.9870; Monogly=0.9841; Ungly=0.9635.
doi:10.1371/journal.pone.0017633.g001
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TM ELISA. Sample
dilutions were processed as per the manufacturer’s instructions,
using the equipment recommended by Bio-RadH Laboratories. All
Bio-RadH Criterion
TM 12% SDS-PAGE gels were run at room
temperature; transfers were continuously cooled to 4uC with a
circulating cooling-coil. MilliporeH Immobilon
TM Western HRP
substrate was used as the test’s chemiluminescent substrate [28].
Blots were detected with x-ray film, GBX developer, and GBX
fixer (Kodak). Films were exposed in the following intervals: 10 s,
20 s, 30 s, 1 m, and 2 m. Films were developed for 3 s, and fixed
for 3 m. The best balanced exposure was selected for analysis.
Scrapie Associated Fibril (S.A.F.)/O.I.E. Immunoblot
(Confirmatory Test). Positive and negative 50%w/v homo-
genates wereresuspended to 25%w/v in brain lysisbuffer (BLB) (10 g
sodium N-laurylsarcosine;1 0 0 m L ,0 . 0 1 Msodium phosphate;p H 7 . 4 )
(Sigma-Aldrich) with 100 mL 100 mM NEM (0.313 g N-ethyl-
maleimide;2 5m L1-propanol) (Sigma-Aldrich), and 100 mL1 0 0m M
PMSF (0.435 g, phenylmethylsulfonyl fluoride;2 5m L ,1-propanol)( S i g m a -
Aldrich). Samples were homogenized using a MediFAST/Prypcon
system. Three drops of 1-octanol (Sigma-Aldrich) was added to each
homogenate to reduce the amount of froth generated by
homogenization. Negative homogenates were pooled, and
aliquoted into 15 mL tubes. The positive homogenate was serially
diluted along the negative homogenates [22,23].
Diluted samples were transferred into Quick-Seal tubes (Beck-
man-Coulter) using a syringe and cannula. Tubes were balanced,
heat-sealed, and loaded into a 70Ti ultracentrifuge rotor (Beck-
man-Coulter). The lysates were then centrifuged (20,000rcf6
30 min; 10uC). The supernatant was collected and transferred to
new Quick-Seal tubes. The tubes were balanced with BLB, heat-
sealed, and centrifuged again (177,000rcf x 2 h15 min; 10uC).
Pellets were vigorously resuspended in 1.5 mL ddH2O plus 25 mL
1 M Tris-HCl. Samples were incubated in a water-bath at 37uC
for 15 m [22,23].
3 mL of 15% KI-HSB (60.4 mM sodium thiosulphate pentahydrate;
36.8 mM N-lauroylsarcosine; 100 mM Tris-HCl [pH 7.4];
903.6 mM potassium iodide) was added to the samples, and
incubated in a water-bath at 37uC for 30 min, with occasional
mixing. Proteinase K (Roche) was added to each dilution to a final
concentration of 10 mg/mL. Tubes were then incubated in a
water-bath at 37uC for 1 h. 4.5 mL of 10% KI-HSB (60.4 mM
sodium thiosulphate pentahydrate; 36.8 mM N-lauroylsarcosine; 100 mM
Tris-HCl [pH 7.4]; 602.4 mM potassium iodide) was added to the
samples. Samples were transferred to Quick-Seal tubes [23].
2 mL of a 20% sucrose cushion (20 g sucrose; 80 mL 10% KI-
HSB) was carefully deposited to the bottom of the tubes containing
the digested samples. Tubes were filled and balanced with 10%
KI-HSB, heat-sealed, and centrifuged at 189,000rcf for 1 h at
10uC. The supernatant was discarded, and the resulting pellets
were resuspended in 40 mLo fPrionicsH PAGE sample buffer.
Samples were transferred to 2 mL microfuge tubes and sonicated
for 30 s, using Virsonic 550 sonicator [23].
Samples were heated at 95uC for 5 m, and loaded onto a 12-
well, 12% SDS-PAGE gel (Invitrogen
TM). The remainder of the
Figure 2. The PrionicsH-Check PrioSTRIP
TM output curve plotted against PrP
sc content in the respective tissue homogenates. Inset text
and arrows indicates detection limitations. R
2=0.9870.
doi:10.1371/journal.pone.0017633.g002
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TM
rapid-test [15,23,24].
Test Performance Evaluation
The unit of measurement used to evaluate the analytical test
sensitivity was a tissue-ratio of milligrams negative-tissue to
milligrams positive-tissue (mg-/mg+). For test platforms requiring
software-based result interpretation, the software output (positive or
negative) was deemed the final result for the manufacturers’ criteria
(Bio-RadH TeSeE
TM ELISA, IDEXXH HerdChek
TM BSE EIA, and
PrionicsH-Check PrioSTRIP
TM). Output values were plotted to attain a
performance curve for each test. Data were fitted with a saturative,
total binding function, accounting for the total multitude of binding
components, as well as any unforeseen non-specific factors:
y~(Bmax:x)=(Kdzx)z(NS:x)zBackground (PRISM v5.0). A
coefficient of determination, R2, was determined for each
curve to support the tests’ consistency and performance.
R2~1{
P
i
(yi{fi)
2=
P
i
(yi{  y y)
2
  
, where
P
i
yi{fi ðÞ
2 is the
sum of squares of the data residuals, and
P
i
(yi{  y y)
2 is the total
sum of squares of the data (PRISM v5.0).
For western-blot protocols (PrionicsH-Check WESTERN
TM, Bio-
RadH TeSeE Western Blot, S.A.F./O.I.E. Immunoblot), blot films
were analyzed using ChemiDoc XRS (Bio-RadH Laboratories).
Manual measurements of PrP
sc glycoform band-densities (intensity
xm m
2) were conducted, and used as a physical property to
measure PrP
sc/antibody binding. A total-binding function
(y~(Bmax:x)=(Kdzx)z(NS:x)zBackground) for the data
was plotted (PRISM v5.0.). R2 values were also determined for
the fitted curves.
Our definition of a false-negative result pertains to a sample
which has been included in a BSE-positive material dilution series
that had generated a result indistinguishable from that of a known
BSE-negative sample. The theoretical L.O.D. refers to the limit for
the penultimate dilution for the test being challenged. This was
identified by visually inspecting the disappearance of bands, as was
as the point the binding curve for the diglycosylated PrP
sc band
intersected the background density of the particular blot. For
ELISA based protocols, this limit was determined when the
binding curve intersected the tests’ mean negative result values.
Results
Rapid Tests
PrionicsH-Check WESTERN
TM. PrionicsH-Check WESTERN
TM
diagnostic criteria for positive results pertain a visible, three band
(signal) pattern, decreasing in intensity from top to bottom, where the
top-band (diglycosylated band) is situated immediately following the
PK-band. Weak-positive criteria consist of the presence of the top-
band, where the distance between the top-band and the PK-band is
more noticeable than usual, as well as lacking the presence of the
second (monoglycosylated) and third (unglycosylated) bands. Negative
results are only lanes without bands (other than the PK-band) and the
kit’s positive control is clearly visible [15,24].
Figure 3. The OD curve for the Bio-Rad H TeSeE
TM ELISA plotted against PrP
sc content in the respective tissue homogenates. Inset text
and arrows indicates detection limitations. R
2=0.9945.
doi:10.1371/journal.pone.0017633.g003
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positive criteria to a tissue-ratio of 1.19610
2 mg2/mg+, where all
glycoform bands were clearly distinguishable from the blot
background. However, the weak-positive could be fulfilled up to
1.28610
3 mg2/mg+, where the top-band was visible just below
the PK-band and no second or third band was present. At
1.79610
3 mg2/mg+, the fitted-curve suggests the result for a
weak positive sample would be indistinguishable from a negative
sample, and is therefore considered the theoretical L.O.D.
Given the semi-subjective nature of western blot interpretation,
individual techniques, reagents and equipment used, the theoret-
ical L.O.D. for blot protocols will likely have a greater degree of
variability within detection margins as compared to the other
ELISA-based rapid-tests. The margin of sensitivity between the
PrionicsH-Check WESTERN
TM and the Bio-Rad
TM TeSeE
TM
ELISA kits is likely narrower than what is reported in this study.
The PrionicsH-Check WESTERN
TM kit was found to be 10 fold
more sensitive if one considers the weak-positive criteria to be the
detection limit, rather than the requirement for all PrP
sc glyco-
forms to be present.
PrionicsH-Check PrioSTRIP
TM. In figure 2, the PrionicsH-
Check PrioSTRIP
TM accurately, and consistently, detected a tissue-
ratio of 3.87610
2 mg2/mg+ as positive above the particular kit-
lot’s cut-off value. Non-zero results could be detected up to—but
not past—1.92610
3 mg2/mg+. This value was the identified
theoretical L.O.D. Because zero is the inarguable negative result,
any value above zero could be considered suspicious. If non-zero
results are treated as initial-reactor samples, the PrionicsH-Check
PrioSTRIP
TM is within the same log-base of detection as the
PrionicsH -Check WESTERN
TM’s weak-positive criteria and the
Bio-Rad
TM TeSeE
TM ELISA.
Bio-RadH TeSeE
TM ELISA. The TeSeE
TM ELISA correctly
identified positive tissues up to a tissue-ratio of 2.18610
3 mg2/
mg+ (figure 3). Although, one dilution did record in between the
positive and negative cut-off criteria (inconclusive), and another
dilution recorded below the negative cut-off. This dilution set was
very close to the curve-derived maximal sensitivity regarding
the tests’ cut-off criteria of ,2.5610
3 mg2/mg+. Beyond
3.90610
3 mg2/mg+, weak-positive dilutions were indisting-
uishable from negative results. This tissue-ratio was taken as the
theoretical L.O.D.
The kit negative control serves to evaluate the performance of
the reagents, and did not reflect the OD value of the negative
tissue stock used in the experiment. The mean OD result of a
negative tissue sample was 10 fold greater than the supplied kit
negative. A confirmed negative tissue control would provide
additional support regarding a base-line OD reference point for
diagnostic samples with elevated negative OD values. Because the
L.O.D. determined in this study was similar to those published in a
previous study [10], these results suggest the lyophilization of the
grinding buffer did not interfere with the TeSeE
TM ELISA’s
performance.
IDEXXH HerdChek
TM BSE EIA. Our results indicate that
the HerdChek
TM possesses a greater sensitivity for the BSE (C-type)
Figure 4. IDEXX HerdCheck
TM BSE EIA OD curve plotted against PrP
sc content in the respective tissue homogenates. Inset text and
arrows indicates detection limitations. R
2=0.9980.
doi:10.1371/journal.pone.0017633.g004
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3 mg2/
mg+ was consistently positive, where the preceding tissue ratio of
1.03610
4 mg2/mg+ had generated both positive and negative
results. The fitted-curve in figure 4 indicates the manufacturer’s cut-
off criterion was met at 8.90610
3 mg2/mg+. The HerdChek
TM
reported at least a full log10 base greater sensitivity compared to
the theoretical L.O.D. for the PrionicsH-Check WESTERN
TM,
PrionicsH-Check PrioSTRIP
TM, and Bio-RadH TeSeE
TM ELISA.
Significantly elevated OD values of false-negative results were
present up to a tissue-ratio of ,3.00610
4 mg2/mg+. Elevated
OD values for false negatives had a range from 0.163 and 0.06,
over which had a 10-fold difference in infectious unit concentra-
tion. Because of the HerdChek
TM BSE EIA’s pseudo-sigmoidal
appearance on the plotted log2-log10 graph, elevated OD values
below the negative cut-off are likely to be more consistently
elevated on test-repeats.
The fitted-curve suggests weak-positive tissue-ratios of 1.16610
5
mg2/mg+, and greater, are indistinguishable from negative-tissue
results. This value was identified at the theoretical L.O.D.
As with the TeSeE
TM ELISA, confirmed negative tissue samples
should be tested alongside diagnostic samples to verify a base-line
for true negative tissues. Because of the Seprion technology
dependence on PrP
sc conformation/tertiary structure for detec-
tion, the test’s performance regarding atypical forms of BSE may
differ in sensitivity as compared to the results within this study
[16,18,19,29].
Confirmatory Tests
Bio-RadH TeSeE
TM Western Blot. The performance of the
Bio-RadH TeSeE
TM Western Blot, shown in figure 5, was highly
sensitive—especially considering the sample purification is
supported to be that of the TeSeE
TM ELISA (Bio-Rad, personal
communication), which is followed by a basic western blot
protocol. Glycoforms were distinguishable up to a tissue ratio of
6.61610
3 mg2/mg+. Non-negative results, or only diglycosylated
bands, were clearly visible up to 3.93610
4 mg2/mg+. A curve-
derived theoretical L.O.D. could be considered viable up to
6.63610
4 mg2/mg, as this was the corresponding tissue-ratio at
which the diglycosylated band’s density curve intersects the mean
background of the blot.
It should be noted that a band remained in the monoglycosy-
lated region of the lane, as the density of the diglycosylated band
decreased into the blot’s background. As a comparative note, this
behaviour parallels the weak-positive criteria outlined for the
PrionicsH-Check WESTERN
TM test [15,24]. This is likely due to an
increased activity of PK on the minute proportion of PrP
sc in these
high dilutions. Increased PK activity would over-digest the PrP
sc in
the homogenate, thus resulting in obscure, depleted PrP
sc
fragments. Smaller diglycosylated PrP
sc peptides may be present-
ing themselves in a weight range between that of the mono-
glycosylated and diglycosylated PrP
sc glycoforms, thereby diluting
the signal within the expected ,30 kDa range. However, for the
purpose of this study, the disappearance of the typical prion blot
Figure 5. The curves depict densities of PrP
sc bands (diglycosylated (Digly), monoglycosylated (Monogly), unglycosylated (Ungly))
in the Bio-Rad H TeSeE
TM Western Blot. (inset) and detection curves for digly-, monogly-, and unglycosylated bands of PrP
sc. Numbers on the
right of each density data point correspond to the numbers in the blot photo (inset). Each label (Digly, Monogly, Ungly) in the inset photo appears to
the left of the band it describes. R
2: Digly=0.9858; Monogly=0.9659; Ungly=0.9857.
doi:10.1371/journal.pone.0017633.g005
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considered to be the detection limit for the test, despite the
presence of other bands in the lane.
S.A.F./O.I.E. Immunoblot. Figure 6 illustrates it was
possible for the S.A.F. to detect a PK resistant, ,30 kDa band
at a tissue ratio of 4.30610
5 mg2/mg+. The theoretical detection
limit determined by the fitted-curve was 1.36610
6 mg2/mg+,
where the mean blot background signal was intersected. The
purification method within the S.A.F./O.I.E immunoblot protocol
enhanced the standard performance of the PrionicsH -Check
WESTERN
TM blot by ,130 fold, for a non-negative sample.
This method remains the most sensitive diagnostic test, clearly
exceeding the performance of the second confirmatory test in this
comparison, as well as the most sensitive surveillance test.
Discussion
Because PrP
sc is an amyloidogenic protein [14], fibrils tend to
adhere to one another in solution, potentially compromising true
homogeneous serial dilutions. Given the fact that all R2 for each
analytical curve was $0.96, and all error margins between
replicates—especially for the ELISA based tests—were quite tight,
this suggests that the data was fit with an appropriate function, and
that the PrP
sc distribution amongst the serial dilutions was fair and
homogeneous, and any potential post-homogenization aggregative
activity between PrP
sc fibrils affecting dilution integrity was
negligible. Slightly lower R2values for the western blot data are
likely attributable to the nature of the manual measurements as
opposed to the automated measurements from ELISA plate
readers.
Diagnosing BSE via western blotting is a well characterized
method; however, samples with very low PrP
sc concentrations
show abnormal banding profiles that do not coincide with the
typical criteria required for a positive diagnosis. A signal for a weak
positive-sample may be given, however the sample could be
diagnosed as negative, if it does not display the anticipated PrP
sc
banding profile. For example, it could be questionable, to some,
whether the diglycosylated band in tissue-ratio #15
(1.28610
3 mg2/mg+)i nfigure 1 is positive. However, if this
sample would be tested on the TeSeE
TM ELISA, the curve in
figure 3 clearly shows the sample would register above the cut-off
limit, and would label it a positive result.
The PrionicsH-Check WESTERN
TM is both a qualitative and
quantitative test, as BSE-types can be distinguished by molecular
weights and glycoform ratios [15,17,22]. It needs to be considered
that a sample on an SDS-PAGE is separated into the three PrP
sc
glycoforms from one another, thus dispersing the signal from all
PrP
sc in the lane, rather than keeping the signal concentrated in one
location. For example, the PrP
sc glycoform ratio for C-type BSE is
approximately 68% diglycosylated PrP
sc, 24% monoglycosylated
PrP
sc, and 8% unglycosylated PrP
sc [17]. This suggests the blot
signal from tissue-ratio #15 (figure 1) only represents approximately
68% of the total prion protein in the lane.
Our results showed the PrionicsH-Check PrioSTRIP
TM performed
similarly to the Bio-RadH TeSeE
TM ELISA. The PrionicsH-Check
Figure 6. The curve depicts densities of PrP
sc bands in the Scrapie Associated Fibrils (S.A.F.)/O.I.E. Immunoblot plotted against PrP
sc
content in the respective tissue homogenates. Numbers on the right of each density data point correspond to the numbers in the blot photo
(inset). R
2=0.999.
doi:10.1371/journal.pone.0017633.g006
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TM is purely a quantitative test—all three prion-protein
glycoforms are concentrated on one area of the immunochroma-
tographic strip, the same way ELISAs concentrate the target
protein on the bottom of the well. Although the Bio-RadH
TeSeE
TM and IDEXXH HerdChek
TM ELISAs use of colorimetric
methods for detection might seem more reliable, the combination
of methods and materials used in the PrionicsH-Check PrioSTRIP
TM
was able to compete within a 2 log10 range of these tests.
Recently, there has been some controversy regarding the
analytical sensitivity, performance, and consistency of the
PrionicsH-Check PrioSTRIP
TM, as compared to other rapid-tests
[20,21]. Although, result output values for tissue-ratios are likely to
vary between kit lots, the reproducibility of results observed within
this study suggests the test platform is respectably consistent, as
demonstrated by the narrow standard error bars seen within
figure 2. The sigmoidal nature of the curve, the high reproducibil-
ity, and R
2 value near 1 depicts the test’s reliability, even at lower
concentrations of PrP
sc in infected tissues.
Our study’s PrionicsH-Check PrioSTRIP
TM results are only based
on the use of the computerized scanning method/software, and
not on the visual manual-reading method. Manual interpretation
of the combs, although an approved method of interpreting results
[25], would not have served well at low positive tissue
concentrations. Visual perceptions and personal bias between
individual readers is likely more subjective than an electronic-
based system, where bias is eliminated. This study would always
support the use of the appropriate scanning software and
equipment, as suggested by PrionicsH.
The ideal performance for a BSE rapid-test kit would
demonstrate a sigmoid-type detection curve, plotted on a logx-
logy graph. Such a test would likely perform more consistently at
lower concentrations of PrP
sc, rather than test platforms with
detection curves decreasing hyperbolically over decreasing PrP
sc
concentrations. For example, the tissue-ratio at the HerdChek
TM’s
cut-off was 8.9610
3 mg2/mg+, and would generate an OD value
of ,0.163. A 2-fold less concentrated sample (,1.78610
4 mg2/
mg+) would generate an OD result of ,0.104. Although this OD
value is below the cut-off criteria, it is still ,2-fold greater than the
mean negative-tissue result. In contrast, the Bio-RadH TeSeE
TM
ELISA’s cut-off OD value of 0.221 corresponds to a tissue-ratio of
,2.53610
3. A 2-fold less concentrated sample would generate an
extrapolated result of 0.082, more than 2.5 fold lower than the cut-
off value, and lower than the mean negative tissue OD of 0.137.
In the aforementioned case, the TeSeE
TM ELISA does not have
as much tolerance for samples reading between the positive cut-off
and the mean OD for a set of negative sample controls, as
compared to the HerdChek
TM’s tolerance for such samples. This
suggests a weak-positive sample tested on a platform like the
HerdChek
TM may stand a better chance of remaining distinguish-
able from the mean negative-sample result, despite potentially
being labelled as ‘‘negative’’ by the X-Chek
TM software. Of course,
this is provided the test diagnostician was critical of each OD value
registering negative, and comparing them to a mean OD from
confirmed negative-tissues.
Figure 7 depicts the relative performance of each test when the
manufacturers’ positive/negative cut-off diagnostic definitions
were respected, as well as the L.O.D we have determined for
each test, being when each test failed to generate any
distinguishing results that could differ from a weak-positive sample
from a true negative-sample.
In conclusion, all BSE rapid screening tests evaluated in this
study are EU/EFSA approved. The results presented within this
study are not preferentially condoning the use of one test over
another. All rapid-tests were able to perform within a 2 log10 range
of one another, and all coincide with EC No. 999/2001
regulations on monitoring BSE prevalence [11]—despite which
Figure 7. A performance summary of both rapid and confirmatory tests. White bars represent the test’s detection limitations, as established
by the manufacturer. Dotted bars represent our determined theoretical limit of detection for each test, where the corresponding positive tissue
dilution yielded a result no different from true negative tissue. Confirmatory tests are above the dashed line. Rapid-tests are below the dashed line.
doi:10.1371/journal.pone.0017633.g007
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well suited for use in targeted surveillance programs, where
animals selected for BSE surveillance are typically exhibiting
suspicious signs of clinical disease. Samples from animals
exhibiting even subtle signs of BSE are most likely to behave as
field samples used in validation exercises used for test approval..
This study elucidates the relative performance of these tests solely
on experimentally generated C-Type BSE, serially diluted in
known BSE-negative tissue homogenate, and not necessarily on C-
type BSE occurring by natural means. No results in this study
pertain to test performance regarding atypical-BSE. Field cases
still have to be given the benefit of the doubt regarding the tests’
true performances. Nonetheless, the presented results are meant to
serve as insight into the test’s performances on samples which are
weak in BSE-positive PrP
sc units.
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